Share this article on:

Conjunctival MALT Lymphoma: Utility of FDG PET/CT for Diagnosis, Staging, and Evaluation of Treatment Response

Sallak, Asmaa MD*; Besson, Florent L. MD*; Pomoni, Anastasia MD*; Christinat, Alexandre MD; Adler, Marcel MD; Aegerter, Jean-Philippe MD; Nguyen, Christophe MD§; de Leval, Laurence MD, PhD; Frossard, Valérie MD; Prior, John O. PhD, MD*

doi: 10.1097/RLU.0000000000000356
Interesting Images

Abstract: A 67-year-old woman was referred for staging of a mucosa-associated lymphoid tumor lymphoma involving the left conjunctiva. CT scan had shown paravertebral and pelvic masses, and a breast nodule. FDG PET/CT demonstrated moderately increased uptake in the left ocular conjunctiva and confirmed the paravertebral and pelvic masses and the breast nodule. Moreover, abnormal FDG uptake was shown in 2 breast nodules, the flank, the gluteus maximus, and the gastric cardia. The patient received 6 cycles of rituximab-bendamustine chemotherapy with a complete clinical and metabolic response at the 6-month follow-up PET/CT and remained relapse-free without visual acuity problem after a 36-month follow-up.

From the Departments of *Nuclear Medicine, †Oncology, and ‡Hematology, Lausanne University Hospital; §Jules Gonin Eye Hospital; ¶Department of Pathology, Lausanne University Hospital, Lausanne; and ∥Department of Oncology, Sion Hospital, Sion, Switzerland.

Received for publication July 8, 2013; revision accepted December 11, 2013.

Conflicts of interest and sources of funding: none declared.

Reprints: John O. Prior, PhD, MD, Department of Nuclear Medicine, Lausanne University Hospital, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland. E-mail:

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Back to Top | Article Outline


1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998; 9: 717–720.
2. Thomas AG, Vaidhyanath R, Kirke R, et al. Extranodal lymphoma from head to toe: part 1, the head and spine. AJR Am J Roentgenol. 2011; 197: 350–356.
3. Matsuo T, Ichimura K, Tanaka T, et al. Conjunctival lymphoma can be detected by FDG PET. Clin Nucl Med. 2012; 37: 516–519.
4. Hayashi D, Devenney-Cakir B, Lee JC, et al. Mucosa-associated lymphoid tissue lymphoma: multimodality imaging and histopathologic correlation. AJR Am J Roentgenol. 2010; 195: W105–W117.
5. Gayed I, Eskandari MF, McLaughlin P, et al. Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy. Ophthalmic Surg Lasers Imaging. 2007; 38: 319–325.
6. Abdelmalik AG, Fajnwaks P, Osman MM, et al. Squamous cell carcinoma of the bulbar conjunctiva seen on F-18 FDG PET/CT. Clin Nucl Med. 2010; 35: 962–964.
7. Lin LF, Chang CY, Cherng SC. Advanced squamous cell carcinoma of the bulbar conjunctiva seen on PET/CT. Clin Nucl Med. 2008; 33: 929–930.
8. Zanni M, Moulin-Romsee G, Servois V, et al. Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience. Hematology. 2012; 17: 76–84.
9. Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. Blood. 2009; 114: 501–510.
10. Dabbagh Kakhki VR. 18F-FDG-PET, gallium-67 and somatostatin receptor scintigraphy, in ocular MALT lymphoma. Hell J Nucl Med. 2008; 11: 49; author reply 50.

18F; FDG; PET; ocular lymphoma; MALT; ocular adnexal MALT lymphoma; conjunctival MALT lymphoma

© 2014 by Lippincott Williams & Wilkins